[Candida albicans morphotypes and in vitro adhesivity to cells of the human oral mucosa in HIV-positive and AIDS patients after exposure of blastospores to fluconazole. II].
BACKGROUND
Oro-pharyngeal candidosis is a frequently initial clinical manifestation of HIV infection and the adhesive properties of Candida spp. represent a very important pathogenicity factor.


METHODS
In this study the adhesivity rate of Candida albicans to the oral epithelial cells of 33 HIV-positive patients and 12 healthy volunteers, have been assessed before and after the exposure of blastospores to inhibitory concentrations of fluconazole, in relation to 11 morphotypes obtained from 13 C. albicans strains.


RESULTS
Results can be summarized as follows: 1) the number of blastospores adhering to the HIV-positive donor' cells is higher than that of blastospores adhering to the healthy donors' cells (rate is 2.7:1); 2) blastospores from strains producing rough or very coarse fringes show adhesive properties higher than those of strains with different morphology; 3) in the group of HIV-positive patients the adhesivity inhibition of blastospores from strains producing rough or very coarse fringes was higher (38.3%) than that of strains with different morphology (33.8%); 4) overall, adhesivity inhibition due to exposure to fluconazole is higher for epithelial cells from healthy donors.


CONCLUSIONS
These results can suggest the validity of an antimycotic pretreatment of persons at risk of oro-pharyngeal candidiasis.
Spadari
E
E
Istituto di Microbiologia Medica, Università degli Studi, Milano.
Arosio
M
M
Malighetti
V
V
Bellotti
M G
MG
Artini
M Z
MZ
Spadari
F
F
Riviera
L
L
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology*; D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use*; D005775:Gastrula / Q000187:drug effects*; D006679:HIV Seropositivity / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008297:Male
D000935:Antifungal Agents; D015725:Fluconazole